For several years, Jimo Borjigin, a professor of neurology at the University of Michigan, had been troubled by the question of what happens to us when we die.
New research into the dying brain suggests the line between life and death may be less distinct than previously thought by Alex Blasdel.
A woman found that her image was being used in “deepfake porn” and the person responsible was a friend.
Electroconvulsive therapy is more effective than ketamine at treating severe depression, according to a new meta-analysis.
AI companies are swiftly running into a massive problem: there isn’t enough data on the internet to train the next generation of models.
A tiny creature that’s sturdy enough to survive space may hold the key to human longevity, scientists have found in a new study.
Google announces Streaming Dense Video Captioning.
An ideal model for dense video captioning — predicting captions localized temporally in a video — should be able to handle long input videos, predict rich, detailed textual descriptions, and be able to…
Join the discussion on this paper page.
The location of the solar system’s outer boundary is a point of contention among astronomers. There are three possible candidates, which “all have merit.” But which one is best?
🧬🔬🐁
New research unveils the paradoxical role of miR-205 in mammary gland development and its potential impact on breast cancer, highlighting the miRNA’s complex involvement in stem cell regulation and tumor suppression.
MONDAY, March 25, 2024 (HealthDay News) — Intrathecal gene transfer with scAAV9/JeT-GAN may result in some benefit for children with giant axonal neuropathy, according to a study published in the March 21 issue of the New England Journal of Medicine.
Diana X. Bharucha-Goebel, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues conducted an intrathecal dose-escalation study of scAAV9/JeT-GAN in children with giant axonal neuropathy. Fourteen participants received one of four intrathecal doses of scAAV9/JeT-GAN: 3.5 × 1013 total vector genomes (vg); 1.2 × 1014 vg; 1.8 × 1014 vg; and 3.5 × 1014 vg (in two, four, five, and three participants, respectively).
The researchers found that during a median observation period of 68.7 months, one of the 48 serious adverse events was possibly related to treatment and 129 of 682 adverse events were possibly related to treatment. In the total cohort, the mean pretreatment slope was −7.17 percentage points per year. One year posttreatment, posterior mean changes in slope were −0.54, 3.23, 5.32, and 3.43 percentage points with the 3.5 × 1013 vg, 1.2 × 1014 vg, 1.8 × 1014 vg, and 3.5 × 1014 vg doses, respectively. For slowing the slope, the corresponding posterior probabilities were 44, 92, 99 (above the efficacy threshold), and 90 percent, respectively. Sensory-nerve action potential amplitudes increased, stopped declining, or became recordable after being absent in six participants between six and 24 months after gene transfer, but remained absent in eight participants.
